The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome.

The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome.
复制标题

DOI:
10.1016/j.humpath.2013.07.026
复制
发表时间:
2013-12
期刊:
影响因子:
3.3
通讯作者:
Anders, Robert A.
Anders, Robert A.
中科院分区:
医学3区
文献类型:
--
作者:
Robertson, Scott;Hyder, Omar;Dodson, Rebecca;Nayar, Suresh K.;Poling, Justin;Beierl, Katie;Eshleman, James R.;Lin, Ming-Tseh;Pawlik, Timothy M.;Anders, Robert A.

文献摘要

参考文献

被引文献

相似文献

肝内胆管细胞癌(ICC)的发病率在世界范围内不断增加。ICC的预后很差,需要更好地了解ICC肿瘤生物学,以更准确地预测临床结果,并为更有效的治疗提供潜在的靶点。v-Ki-ras 2 Kirsten大鼠肉瘤病毒癌基因同源物(KRAS)和BRAF是经常突变的癌基因,其促进多种肿瘤类型中的致癌作用。在这项研究中,我们分析了大量ICC肿瘤(N = 54)中这些基因的突变,并比较了野生型与KRAS和BRAF突变病例的临床结果。在54例病例中,7.4%的KRAS突变,7.4%的BRAF突变,这些是相互排斥的。这些突变病例与切除时较高的肿瘤分期和淋巴结受累的可能性较大相关。这些病例也与长期总生存率较差相关。因此,检测KRAS和BRAF突变可能是改善ICC患者预后和结局分层的有价值的辅助手段。
The incidence of intrahepatic cholangiocarcinoma (ICC) is increasing worldwide. The prognosis of ICC is poor and a better understanding of ICC tumor biology is needed to more accurately predict clinical outcome and to suggest potential targets for more effective therapies. v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) and BRAF are frequently mutated oncogenes that promote carcinogenesis in a variety of tumor types. In this study, we analyze a large set of ICC tumors (N = 54) for mutations in these genes and compare the clinical outcomes of wild type versus KRAS and BRAF mutant cases. Out of 54 cases, 7.4% were mutant for KRAS, 7.4% were mutant for BRAF and these were mutually exclusive. These mutant cases were associated with a higher tumor stage at time of resection and a greater likelihood of lymph node involvement. These cases were also associated with a worse long-term overall survival. Therefore, testing for KRAS and BRAF mutations could be a valuable adjunct in improving both prognosis and outcome stratification among patients with ICC.
DOI: 10.1053/j.gastro.2013.01.001
发表时间: 2013-04
期刊: Gastroenterology
影响因子: 29.4
作者:
Sia D;Hoshida Y;Villanueva A;Roayaie S;Ferrer J;Tabak B;Peix J;Sole M;Tovar V;Alsinet C;Cornella H;Klotzle B;Fan JB;Cotsoglou C;Thung SN;Fuster J;Waxman S;Garcia-Valdecasas JC;Bruix J;Schwartz ME;Beroukhim R;Mazzaferro V;Llovet JM
通讯作者: Llovet JM
DOI: 10.1111/j.1349-7006.2004.tb02492.x
发表时间: 2004-07-01
期刊: CANCER SCIENCE
影响因子: 5.7
作者:
Yamamoto, S;Kubo, S;Tanaka, T
通讯作者: Tanaka, T
DOI: 10.1093/oxfordjournals.annonc.a010676
发表时间: 1996-08-01
期刊: ANNALS OF ONCOLOGY
影响因子: 50.5
作者:
Glimelius, B;Hoffman, K;Svensson, C
通讯作者: Svensson, C
DOI: 10.1016/j.suc.2010.04.011
发表时间: 2010-08-01
影响因子: 3.1
作者:
Poultsides, George A.;Zhu, Andrew X.;Pawlik, Timothy M.
通讯作者: Pawlik, Timothy M.
DOI: 10.1016/j.humpath.2012.11.006
发表时间: 2013-07-01
期刊: HUMAN PATHOLOGY
影响因子: 3.3
作者:
Voss, Jesse S.;Holtegaard, Leonard M.;Kipp, Benjamin R.
通讯作者: Kipp, Benjamin R.